Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02734004
Title	A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA)
Acronym	MEDIOLA
Recruitment	Active, not recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	AstraZeneca
Indications	stomach cancer breast cancer ovarian cancer lung small cell carcinoma
Therapies	Durvalumab + Olaparib Bevacizumab + Durvalumab + Olaparib
Age Groups:	adult \| senior
Covered Countries	USA \| NLD \| ISR \| GBR \| FRA \| CHE